CURLF Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -17.03% compared to Curaleaf Holdings, Inc.'s net margin of 16.99%. Curaleaf Holdings, Inc.'s return on equity of -25.2% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Curaleaf Holdings, Inc. has a consensus price target of $4.05, signalling upside risk potential of 55.17%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Curaleaf Holdings, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Curaleaf Holdings, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Curaleaf Holdings, Inc. has a beta of 0.907, which suggesting that the stock is 9.299% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Curaleaf Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Curaleaf Holdings, Inc. quarterly revenues are $320.2M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Curaleaf Holdings, Inc.'s net income of -$54.5M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Curaleaf Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings, Inc. is 1.54x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -17.03% compared to Curaleaf Holdings, Inc.'s net margin of -3.91%. Curaleaf Holdings, Inc.'s return on equity of -25.2% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

Curaleaf Holdings, Inc. has a consensus price target of $4.05, signalling upside risk potential of 55.17%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Curaleaf Holdings, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Curaleaf Holdings, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

Curaleaf Holdings, Inc. has a beta of 0.907, which suggesting that the stock is 9.299% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Curaleaf Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Curaleaf Holdings, Inc. quarterly revenues are $320.2M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Curaleaf Holdings, Inc.'s net income of -$54.5M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Curaleaf Holdings, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings, Inc. is 1.54x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -17.03% compared to Curaleaf Holdings, Inc.'s net margin of --. Curaleaf Holdings, Inc.'s return on equity of -25.2% beat Savara, Inc.'s return on equity of -78.83%.

Curaleaf Holdings, Inc. has a consensus price target of $4.05, signalling upside risk potential of 55.17%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that Savara, Inc. has higher upside potential than Curaleaf Holdings, Inc., analysts believe Savara, Inc. is more attractive than Curaleaf Holdings, Inc..

Curaleaf Holdings, Inc. has a beta of 0.907, which suggesting that the stock is 9.299% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Curaleaf Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Curaleaf Holdings, Inc. quarterly revenues are $320.2M, which are larger than Savara, Inc. quarterly revenues of --. Curaleaf Holdings, Inc.'s net income of -$54.5M is lower than Savara, Inc.'s net income of -$29.6M. Notably, Curaleaf Holdings, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings, Inc. is 1.54x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of -17.03% compared to Curaleaf Holdings, Inc.'s net margin of -20%. Curaleaf Holdings, Inc.'s return on equity of -25.2% beat Tilray Brands, Inc.'s return on equity of -98.18%.

Curaleaf Holdings, Inc. has a consensus price target of $4.05, signalling upside risk potential of 55.17%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.83 which suggests that it could grow by 49.87%. Given that Curaleaf Holdings, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Curaleaf Holdings, Inc. is more attractive than Tilray Brands, Inc..

Curaleaf Holdings, Inc. has a beta of 0.907, which suggesting that the stock is 9.299% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 2.022, suggesting its more volatile than the S&P 500 by 102.181%.

Curaleaf Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.

Curaleaf Holdings, Inc. quarterly revenues are $320.2M, which are larger than Tilray Brands, Inc. quarterly revenues of $217.5M. Curaleaf Holdings, Inc.'s net income of -$54.5M is lower than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Curaleaf Holdings, Inc.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings, Inc. is 1.54x versus 0.95x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.